RIGEL PHARMACEUTICALS, INC. Retained Earnings
RIGEL PHARMACEUTICALS, INC. (RIGL) had Retained Earnings of -$997.10 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-04
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$997.10M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$1.01B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$1.02B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$1.29B.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$997.10M 10-Q · filed 2026-08-04 |
| 2026-03-31 | -$1.01B 10-Q · filed 2026-05-05 |
| 2025-12-31 | -$1.02B 10-Q · filed 2026-08-04 |
| 2025-09-30 | -$1.29B 10-Q · filed 2025-11-04 |
| 2025-06-30 | -$1.32B 10-Q · filed 2025-08-05 |
| 2025-03-31 | -$1.38B 10-Q · filed 2025-05-06 |
| 2024-12-31 | -$1.39B 10-K · filed 2026-03-03 |
| 2024-09-30 | -$1.40B 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$1.42B 10-Q · filed 2024-08-06 |
| 2024-03-31 | -$1.42B 10-Q · filed 2024-05-07 |
| 2023-12-31 | -$1.41B 10-K · filed 2025-03-04 |
| 2023-09-30 | -$1.41B 10-Q · filed 2023-11-07 |
| 2023-06-30 | -$1.40B 10-Q · filed 2023-08-01 |
| 2023-03-31 | -$1.40B 10-Q · filed 2023-05-02 |
| 2022-12-31 | -$1.38B 10-K · filed 2024-03-05 |
| 2022-09-30 | -$1.38B 10-Q · filed 2022-11-03 |
| 2022-06-30 | -$1.36B 10-Q · filed 2022-08-02 |
| 2022-03-31 | -$1.35B 10-Q · filed 2022-05-03 |
| 2021-12-31 | -$1.32B 10-K · filed 2023-03-07 |
| 2021-09-30 | -$1.30B 10-Q · filed 2021-11-02 |
| 2021-06-30 | -$1.28B 10-Q · filed 2021-08-03 |
| 2021-03-31 | -$1.27B 10-Q · filed 2021-05-05 |
| 2020-12-31 | -$1.31B 10-K · filed 2022-03-01 |
| 2020-09-30 | -$1.29B 10-Q · filed 2020-11-05 |
| 2020-06-30 | -$1.27B 10-Q · filed 2020-08-04 |
| 2020-03-31 | -$1.25B 10-Q · filed 2020-05-05 |
| 2019-12-31 | -$1.28B 10-K · filed 2021-03-02 |
| 2019-09-30 | -$1.26B 10-Q · filed 2019-11-05 |
| 2019-06-30 | -$1.25B 10-Q · filed 2019-08-06 |
| 2019-03-31 | -$1.23B 10-Q · filed 2019-05-07 |
| 2018-12-31 | -$1.21B 10-K · filed 2020-02-27 |
| 2018-09-30 | -$1.21B 10-Q · filed 2018-11-06 |
| 2018-06-30 | -$1.19B 10-Q · filed 2018-08-08 |
| 2018-03-31 | -$1.16B 10-Q · filed 2018-05-01 |
| 2017-12-31 | -$1.14B 10-K · filed 2019-02-28 |
| 2017-09-30 | -$1.11B 10-Q · filed 2017-11-07 |
| 2017-06-30 | -$1.10B 10-Q · filed 2017-08-01 |
| 2017-03-31 | -$1.08B 10-Q · filed 2017-05-02 |
| 2016-12-31 | -$1.06B 10-K · filed 2018-03-06 |
| 2016-09-30 | -$1.05B 10-Q · filed 2016-11-01 |
| 2016-06-30 | -$1.02B 10-Q · filed 2016-08-02 |
| 2016-03-31 | -$1.01B 10-Q · filed 2016-05-03 |
| 2015-12-31 | -$991.65M 10-K · filed 2017-03-07 |
| 2015-09-30 | -$978.96M 10-Q · filed 2015-11-03 |
| 2015-06-30 | -$972.29M 10-Q · filed 2015-08-04 |
| 2015-03-31 | -$958.38M 10-Q · filed 2015-05-07 |
| 2014-12-31 | -$940.18M 10-K · filed 2016-03-08 |
| 2014-09-30 | -$917.91M 10-Q · filed 2014-11-04 |
| 2014-06-30 | -$896.97M 10-Q · filed 2014-08-05 |
| 2014-03-31 | -$871.58M 10-Q · filed 2014-05-07 |
| 2013-12-31 | -$849.27M 10-K · filed 2015-03-03 |
| 2013-09-30 | -$832.41M 10-Q · filed 2013-11-05 |
| 2013-06-30 | -$808.59M 10-Q · filed 2013-08-06 |
| 2013-03-31 | -$785.82M 10-Q · filed 2013-05-07 |
| 2012-12-31 | -$760.25M 10-K · filed 2014-03-04 |
| 2012-09-30 | -$734.77M 10-Q · filed 2012-11-06 |
| 2012-06-30 | -$709.32M 10-Q · filed 2012-08-07 |
| 2012-03-31 | -$684.58M 10-Q · filed 2012-05-01 |
| 2011-12-31 | -$661.41M 10-K · filed 2013-03-05 |
| 2011-09-30 | -$635.62M 10-Q · filed 2011-11-01 |
| 2011-06-30 | -$617.69M 10-Q · filed 2011-08-02 |
| 2010-12-31 | -$575.43M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |